Overview

Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies
Phase:
Early Phase 1
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Treatments:
Antibodies
Antibodies, Antiphospholipid
Quercetin